Overview

Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer

Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This study was a prospective, single-arm, open-label phase II clinical trial conducted at National cancer center in China.
Phase:
Phase 2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Treatments:
Capecitabine
Vinorelbine